NVCR NovoCure Limited

+0.00  (0%)
Previous Close 13.05
Open 13.30
Price To book 8.92
Market Cap 1.15B
Shares 88,149,000
Volume 674,962
Short Ratio 14.91
Av. Daily Volume 964,184

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PMA approval July 2016.
Optune system
Glioblastoma - cancer
Phase 3 commencement of enrollment announced February 15, 2017. Data due 2021.
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)
Phase 2 data presented December 12, 2016. Further promising PFS data released March 31, 2017. Phase 3 trial to be initiated in 2018.
Tumor Treating Fields (TTFields) - INNOVATE
Ovarian cancer
Phase 2 data presented December 12, 2016. Phase 3 trial to be initiated 2H 2017.
Tumor Treating Fields (TTFields) - PANOVA
Pancreatic cancer
Phase 3 enrollment commenced October 2016. Data due 2020.
Tumor Treating Fields (TTFields) METIS
Brain Metastases Originating from Non-Small Cell Lung Cancer
Phase 2 enrollment completion announced March 31, 2017. Data likely 2Q 2018.
Tumor Treating Fields (TTFields) STELLAR

Latest News

  1. Shark Bites: Focus on the 'Little Picture'
  2. Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma
  3. Martin J. Madden Joins Novocure Board of Directors
  4. Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients
  5. Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas
  6. Edited Transcript of NVCR earnings conference call or presentation 27-Apr-17 12:00pm GMT
  7. ETFs with exposure to Novocure Ltd. : May 1, 2017
  8. Novocure to Present at Three Upcoming Investor Conferences in May
  9. Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting
  10. Novocure Ltd. :NVCR-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
  11. NovoCure reports 1Q loss
  12. Novocure Reports First Quarter 2017 Financial Results and Provides Company Update
  13. Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston
  14. Novocure says drug shows better survival rates for cancer patients in late-stage trial
  15. CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence
  16. 5 Top Stocks to Buy in April
  17. What Investors Missed in the Market This Week
  18. Endo international, AngioDynamics Lead Biotech Movers
  19. ETFs with exposure to Novocure Ltd. : April 5, 2017
  20. Novocure and Cyclacel Pharmaceuticals Surge on Positive FDA Trial News